

Estimate changes



TP change



Rating change



Bloomberg	DABUR IN
Equity Shares (m)	1772
M.Cap.(INRb)/(USD\$)	1140.5 / 13.6
52-Week Range (INR)	662 / 489
1, 6, 12 Rel. Per (%)	2/1/-14
12M Avg Val (INR M)	1453

Financials & Valuations (INR b)

Y/E March	2024	2025E	2026E
Sales	124.0	135.6	149.1
Sales Gr. (%)	7.5	9.3	9.9
EBITDA	24.0	27.1	30.5
EBITDA mrg. (%)	19.4	20.0	20.5
Adj. PAT	18.8	21.0	23.4
Adj. EPS (INR)	10.6	11.8	13.2
EPS Gr. (%)	9.2	11.8	11.8
BV/Sh.(INR)	55.7	60.3	64.8

Ratios

RoE (%)	19.9	20.4	21.1
RoCE (%)	17.3	18.3	19.5
Payout (%)	63.3	69.3	73.3

Valuation

P/E (x)	60.8	54.4	48.7
P/BV (x)	11.6	10.7	9.9
EV/EBITDA (x)	44.9	39.2	34.6
Div. Yield (%)	1.0	1.3	1.5

Shareholding pattern (%)

As On	Jun-24	Mar-24	Jun-23
Promoter	66.3	66.3	66.2
DII	13.6	12.6	8.9
FII	15.0	15.8	19.4
Others	5.2	5.4	5.5

FII Includes depository receipts

CMP: INR644

TP: INR750 (+17%)

Buy

Steady performance; expects further growth pickup

- Dabur's 1QFY25 performance was largely in line with our estimates. Consolidated revenue increased 7% YoY (in line), while constant currency (cc) growth was 10%. India volume grew by 5% YoY, with most categories seeing a pickup in QoQ growth, except the beverage portfolio (affected by heatwaves). International business grew 18% YoY in cc.
- GM improved 120bp YoY to 47.8% (in line). Conversely, high A&P spending (up 15% YoY) restricted EBITDA margin expansion at 25bp YoY to 19.6% (est. 19.6%). EBITDA growth was 8% YoY.
- Besides demand improvement, Dabur's own initiatives for distribution, new launches, and marketing spending will further boost growth. Operating margin also has scope for improvement in the medium term, as it has been hovering around the ~20% band for the last eight to nine years, while peers have enjoyed expansion. **We value Dabur at 55x Jun'26E EPS (earlier 50x) to arrive at our TP of INR750. We reiterate our BUY rating on the stock.**

In-line performance; volume up 5%

- **Dabur reported 7% YoY growth:** Consolidated sales grew 7% (in line) to INR33.5b (est. INR33.7b), up 10% in CC. EBITDA/PBT/adj. PAT each grew by 8% YoY to INR6.6b/INR6.4b/INR5.1b (est. INR6.6b/INR6.5b/INR4.9b). Domestic volume growth (including Badshah) was 5.2%.
- **HPC business sustained healthy growth of 8% YoY:** Oral care clocked 11% growth. Dabur Red and Miswak saw 12%/18% growth. Dabur Red Toothpaste continued to gain market share. Hair Oil, Home Care, Shampoo, and Skin Care posted 3%, 8%, 14%, and 6% YoY growth, respectively.
- **F&B reported slow 4% YoY growth:** Food business delivered 21% growth, while beverages posted muted 3% YoY growth. Beverages were hit by heat waves as consumers preferred other thirst-quenching products. Badshah revenue was up 15% YoY. Healthcare portfolio grew 7%, driven by an 11% increase in digestives. Health supplements rose 8% YoY. Dabur Glucose surged over 30% due to a harsh summer (gained 70bp market share).
- **Improvement in margin:** Gross margin expanded 120bp YoY to 47.8% (est. 47.6%). As a percentage of sales, ad spending was up 50bp YoY at 7%, other expenses rose 30bp YoY to 12%, and staff costs grew 15bp YoY to 10%. EBITDA margin expanded by 25bp to 19.6% (est. 19.6%).
- **International business delivered double-digit growth:** In CC terms, international business grew 18.4%. Egypt business grew 63.7%, while Turkey business was up 19% and the MENA markets posted 13% growth. The Sub-Saharan Africa business rose 9.2%.

Highlights from the management commentary

- The FMCG industry has been seeing a gradual pickup in rural markets for the past two quarters.
- Volume growth has been increasing sequentially, with a 5.2% increase in 1Q and no slowdown in volume growth in Jul'24.

Naveen Trivedi – Research Analyst (Naveen.Trivedi@motilaloswal.com)

Research Analyst: Pratik Prajapati (pratik.prajapati@motilaloswal.com) | **Tanu Jindal** (Tanu.Jindal@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- In rural areas, consumption is recovering thanks to decreasing inflation, increasing elasticity of demand, good harvest, normal monsoon, and government initiatives.
- The shampoo segment grew by 14%, driven by the strong performance of the Vatika brand. The hair oil category grew by 3.3%, with coconut oil posting a strong 20% growth. The oral care portfolio recorded a growth of 11.4%, with Dabur Red growing at 12% and Miswak growing by 18%.
- E-commerce and modern trade posted robust double-digit growth and now contribute ~20% to India business.

Valuation and view

- There are no material changes to our FY25/FY26 estimates.
- Unlike other FMCG companies, Dabur has consistently witnessed higher rural growth compared to urban regions. With an improving volume trajectory and no price-cut impact on revenue (unlike peers), we expect revenue growth outperformance to sustain in the near term. operating margin also has scope for improvement in the medium term as it has been hovering around the ~20% band for the last eight to nine years (unlike peers that enjoyed expansion). **We value Dabur at 55x Jun'26E EPS (earlier 50x) to arrive at our TP of INR750. We reiterate our BUY rating on the stock.**

Quarterly Performance (Consolidated)

												(INR m)
Y/E March	FY24				FY25E				FY24	FY25E	FY25E	Var.
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1QE	(%)
Domestic FMCG vol. growth (%)	3.0	3.0	4.0	3.0	5.2	6.0	7.0	7.0	3.3	5.5	6.0	
Net sales	31,305	32,038	32,551	28,146	33,491	34,965	35,920	31,251	1,24,040	1,35,627	33,653	-0.5%
YoY change (%)	10.9	7.3	6.7	5.1	7.0	9.1	10.4	11.0	7.5	9.3	7.5	
Gross profit	14,588	15,482	15,823	13,679	16,005	16,958	17,529	15,288	59,571	65,779	16,019	-0.1%
Margin (%)	46.6	48.3	48.6	48.6	47.8	48.5	48.8	48.9	48.0	48.5	47.6	
EBITDA	6,047	6,609	6,678	4,668	6,550	7,482	7,723	5,377	24,002	27,132	6,596	-0.7%
Margins (%)	19.3	20.6	20.5	16.6	19.6	21.4	21.5	17.2	19.4	20.0	19.6	
YoY growth (%)	11.2	10.0	8.1	13.9	8.3	13.2	15.6	15.2	10.5	13.0	9.1	
Depreciation	966	983	969	1,074	1,091	1,085	1,085	1,082	3,992	4,343	1,001	
Interest	243	281	365	352	327	300	200	123	1,242	950	300	
Other income	1,098	1,164	1,274	1,289	1,294	1,350	1,450	1,451	4,824	5,545	1,208	
PBT	5,936	6,508	6,618	4,531	6,427	7,447	7,888	5,622	23,593	27,384	6,503	-1.2%
Tax	1,368	1,443	1,550	1,114	1,481	1,787	1,893	1,274	5,474	6,436	1,561	
Rate (%)	23.0	22.2	23.4	24.6	23.0	24.0	24.0	22.7	23.2	23.5	24.0	
Adjusted PAT	4,721	5,233	5,225	3,578	5,084	5,800	6,135	3,959	18,757	20,978	4,942	2.9%
YoY change (%)	7.2	6.7	7.8	10.8	7.7	10.8	17.4	10.7	9.3	11.8	4.7	
Reported PAT	4,639	5,151	5,142	3,495	5,001	5,718	6,052	3,876	18,427	20,651	4,859	2.9%

E: MOFSL Estimates

Key Performance Indicators

Y/E March	FY24				FY25
	1Q	2Q	3Q	4Q	1Q
Realization Gr %	7.9	4.3	2.7	2.1	1.8
2Y average growth %					
Volumes	4.0	2.0	0.5	2.0	4.1
Sales	9.5	6.6	5.1	5.7	8.9
EBITDA	4.9	3.4	2.7	2.1	9.8
PAT	4.0	2.0	1.4	0.5	5.4
% sales					
COGS	53.4	51.7	51.4	51.4	52.2
Other expenditure	27.3	27.7	28.1	32.0	28.2
Depreciation	3.1	3.1	3.0	3.8	3.3
YoY change %					
COGS	9.4	1.5	0.9	-0.3	4.6
Other expenditure	13.8	17.6	18.0	10.3	10.7
Other income	9.2	-5.6	26.3	6.7	17.9
EBIT	16.2	17.6	17.5	12.8	16.3

Exhibit 1: Category-wise performance

Business Segment	Category	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25
Healthcare	Health Supplements	5.5	Flat	Flat	(9.1)	7.8
	Digestives	14.3	18.1	15.1	16.0	10.7
	OTC & Ethical	24.3	8.4	(3.0)	0.6	3.7
Home and Personal Care	Oral Care	13.0	4.1	8.1	22.0	11.4
	Hair Oils	10.0	4.0	4.5	(2.5)	3.3
	Shampoo	9.0	4.1	11.3	6.1	13.7
	Home care	14.5	15.1	6.6	7.5	8.0
	Skin & Salon	3.5	5.0	4.5	0.6	6.1
Foods	Beverages	(2.0)	(10.0)	6.9	(1.5)	2.8
	Foods	35.0	40.0	22.0	20.7	21.3

Sources: Company reports, MOFSL

**Highlights from the management commentary****Environment and outlook**

- The FMCG industry has been witnessing a gradual pickup in rural markets for the past two quarters.
- Volume growth has been increasing sequentially, with a 5.2% increase in Q1 and no slowdown in volume growth in Jul'24.
- In rural areas, consumption is recovering thanks to decreasing inflation, increasing elasticity of demand, good harvest, normal monsoon, and government initiatives.
- E-commerce and modern trade posted robust double-digit growth and now contribute ~20% to India business.
- Modern trade margins are now in line with GT margins. E-commerce margins are in line with GT margins, with some negotiation for margin reduction.
- The company has created bundles of INR10 and accessible price points across different portfolios, which have done well in emerging channels.
- The international business recorded strong growth of 18.4% in CC.
- In international markets, Dabur reported 19% YoY growth in Turkey, 64% in Egypt, 13% in MENA, 21% in SFA business, and 25% in Bangladesh.
- The international business of Badshah declined due to supply chain constraints.
- Food inflation is currently high, and the company may need to take price increases in the food segment.
- Inventory levels are gradually and slowly coming down, which had previously filled up.

Cost and margins

- Gross margins expanded by 120bp, driven by moderation in inflation and cost-savings initiatives.
- A&P expenditure increased by ~16% during the quarter, with digital spending now accounting for more than 30% of overall media expenditures.
- The company is committed to investing in its brands, which may impact gross margins, but expects operating margins to grow beyond 19.6%.
- Gross margins for Badshah have improved by 500bps.
- The company anticipates a deflationary environment in 2Q, which should help maintain flat inflation, but expects inflation to return in 3Q and 4Q.

Segmental highlights

HPC

- The portfolio achieved 8.1% growth.
- Shampoo segment grew by 14%, driven by the strong performance of the Vatika brand.
- Hair oil category grew by 3.3%, with coconut oil posting a strong 20% growth.
- Perfumed hair oils outperformed the category, gaining ~100bp market share.
- Oral care portfolio recorded a growth of 11.4%, with Dabur Red growing by 12% and Miswak growing by 18%.
- Dabur Red Toothpaste continued to gain market share during the quarter, with Dabur Oral K products reaching one out of every two households in the country.
- The company has compared and contrasted its prices with competitors' prices across all SKUs and identified opportunities to not lose share in oral care.
- Home care segment achieved 8% growth during the quarter.
- Odonil saw high single-digit growth, with particularly strong performance in aerosol and gel formats. It recently launched Odomos liquid vaporizer.
- Skincare segment grew by 8%, driven by Gulabari, which saw double-digit growth.

Healthcare


- The healthcare portfolio grew by 7%, driven by an 11% increase in the digestive segment.
- Health supplements also saw a 7.8% rise YoY. Dabur Glucose, a key brand in the health supplements portfolio, surged by over 30% amid harsh summer conditions, gaining 70bp in market share.
- The OTC and ethical category, health juices, baby care, and branded ethical products all clocked double-digit growth.
- There were adverse effects of heatwaves on brands like Shilajit and Honey during the quarter.
- The company continues to focus on consumer-centric engagement initiatives, strengthen doctor advocacy channels, and launch innovative campaigns aimed at reinforcing relevance and expanding market penetration in the healthcare business.

Food & beverages

- The food and beverage segment grew by 4%, with the foods business showing exceptional performance at 21% growth.
- Badshah also reported strong YoY growth of 15%.
- The drink portfolio grew in double digits.
- The J&N segment was impacted by heatwave, leading to a shift in consumer preference toward thirst-quenching products like carbonated beverages.
- In the JNN segment, its market share expanded by 330bp.
- In Badshah, Dabur cut prices due to a softening in commodity prices.

Key exhibits

Exhibit 2: Domestic FMCG business volumes up 5% YoY in 1QFY25



Sources: Company reports, MOFSL

Exhibit 3: Consolidated reported net sales grew 7% YoY to INR33.5b




Exhibit 4: Con. GP margin expanded 120bp YoY to 47.8%




Exhibit 5: EBITDA margin expanded 25bp YoY to 19.6%




Exhibit 6: A&P spending/staff costs/other expenses increased 50bp/15bp/30bp YoY in 1QFY25





Exhibit 7: Consolidated adjusted PAT increased 3.5% YoY to INR4.9b

Sources: Company reports, MOFSL


Valuation and view

- There are no material changes to our FY25/FY26 estimates.
- Unlike other FMCG companies, Dabur has consistently witnessed a higher rural growth compared to urban regions. With an improving volume trajectory and no price cut impact on revenue (unlike peers), we expect revenue growth outperformance to sustain in the near term. Operating margin also has scope for improvement in the medium term, as it has been hovering around the ~20% band, for the last eight to nine years, while peers have enjoyed expansion. **We value Dabur at 55x Jun'26E EPS (earlier 50x) to arrive at our TP of INR750. We reiterate our BUY rating on the stock.**


Exhibit 8: There are no material changes to our FY25E/FY26E estimates

	New		Old		% Change	
	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Net Sales	135.6	149.1	135.6	148.9	0.0	0.1
EBITDA	27.1	30.5	27.5	30.4	-1.5	0.1
Adjusted PAT	21.0	23.4	21.4	23.5	-2.1	-0.2

Source: MOFSL

Exhibit 9: DABUR's P/E (x)

Sources: Bloomberg, MOFSL

Exhibit 10: Consumer sector P/E (x)

Sources: Bloomberg, MOFSL

Financials and valuations

Consol. Income Statement

(INR m)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Net Sales	85,150	86,846	95,683	1,08,960	1,15,379	1,24,040	1,35,627	1,49,071	1,62,723
Change (%)	10.3	2.0	10.2	13.9	5.9	7.5	9.3	9.9	9.2
Gross Profit	42,240	43,434	47,944	52,563	52,692	59,571	65,779	72,747	79,734
Margin (%)	49.6	50.0	50.1	48.2	45.7	48.0	48.5	48.8	49.0
Other Expenditure	24,845	25,510	27,700	29,952	30,971	35,568	38,647	42,262	46,132
EBITDA	17,395	17,924	20,243	22,611	21,721	24,002	27,132	30,485	33,602
Change (%)	7.5	3.0	12.9	11.7	-3.9	10.5	13.0	12.4	10.2
Margin (%)	20.4	20.6	21.2	20.8	18.8	19.4	20.0	20.5	20.7
Depreciation	1,769	2,205	2,401	2,529	3,110	3,992	4,343	4,110	4,316
Int. and Fin. Charges	596	495	308	386	782	1,242	950	850	700
Other Income - Recurring	2,962	3,053	3,253	3,932	4,454	4,824	5,545	5,993	6,692
Profit before Taxes	17,992	18,277	20,787	23,628	22,283	23,593	27,384	31,518	35,278
Change (%)	5.4	1.6	13.7	13.7	-5.7	5.9	16.1	15.1	11.9
Margin (%)	21.1	21.0	21.7	21.7	19.3	19.0	20.2	21.1	21.7
Tax	4,070	4,654	3,630	4,422	4,816	5,395	6,356	7,573	8,696
Deferred Tax	-1,284	-1,857	-20	842	357	79	80	41	12
Tax Rate (%)	15.5	15.3	17.4	22.3	23.2	23.2	23.5	24.2	24.7
Profit after Taxes	15,206	15,480	17,176	18,364	17,110	18,118	20,949	23,905	26,570
Change (%)	10.8	1.8	11.0	6.9	-6.8	5.9	15.6	14.1	11.1
Margin (%)	17.9	17.8	18.0	16.9	14.8	14.6	15.4	16.0	16.3
Minority Interest	30	25	17	31	-58	-314	299	345	387
Adjusted PAT	15,176	15,454	17,160	18,333	17,168	18,757	20,978	23,447	26,068
Exceptional Items	-753	-1,000	0	-850	16	-5	0	0	0
Reported PAT	14,423	14,454	17,160	17,483	17,184	18,427	20,651	23,117	25,738

Balance Sheet

(INR m)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Share Capital	1,766	1,767	1,767	1,768	1,772	1,772	1,772	1,772	1,772
Reserves	54,551	64,290	74,868	82,045	87,961	96,891	1,05,082	1,13,128	1,21,178
Net Worth	56,317	66,057	76,635	83,813	89,733	98,663	1,06,854	1,14,900	1,22,950
Minority Interest	314	365	367	406	4,682	4,368	4,069	3,724	3,337
Loans	5,288	4,718	4,847	10,072	11,434	11,581	11,381	11,181	10,981
Capital Employed	61,919	71,140	81,849	94,291	1,05,848	1,14,612	1,22,304	1,29,805	1,37,268
Gross Block	28,028	32,935	35,238	39,265	53,541	59,488	55,089	57,889	60,689
Less: Accum. Depn.	-11,698	-13,768	-16,169	-18,698	-21,807	-25,799	-29,702	-33,812	-38,129
Net Fixed Assets	16,330	19,167	19,069	20,568	31,734	33,689	25,386	24,076	22,560
Capital WIP	638	1,466	1,473	1,675	1,751	2,091	2,091	2,091	2,091
Goodwill	3,361	3,360	3,360	2,512	4,053	4,051	3,551	3,051	2,551
Investments	33,588	28,003	41,484	62,102	62,574	69,254	71,754	74,254	76,754
Current	7,254	13,910	7,460	8,546	7,365	16,666	19,166	21,666	24,166
Non-current	26,334	14,092	34,024	53,556	55,210	52,588	52,588	52,588	52,588
Curr. Assets, L&A	30,451	41,325	42,199	35,983	37,854	42,079	58,365	68,683	79,230
Inventory	13,005	13,796	17,343	19,114	20,242	19,470	24,221	26,352	28,512
Account Receivables	8,336	8,139	5,616	6,462	8,488	8,987	9,827	10,801	11,790
Cash and Bank Balance	3,282	8,114	12,710	5,387	4,703	6,664	16,805	23,416	30,163
Others	5,828	11,277	6,531	5,021	4,422	6,958	7,513	8,114	8,765
Curr. Liab. and Prov.	22,216	22,226	26,484	27,732	31,229	35,525	37,816	41,323	44,890
Current Liabilities	19,812	19,475	23,126	23,884	28,446	32,343	33,437	36,752	40,118
Provisions	2,404	2,751	3,357	3,847	2,784	3,182	4,379	4,571	4,772
Net Current Assets	8,235	19,099	15,716	8,251	6,625	6,554	20,549	27,360	34,340
Deferred Tax Liability	-231	46	747	-816	-889	-1,027	-1,027	-1,027	-1,027
Application of Funds	61,919	71,140	81,849	94,291	1,05,848	1,14,611	1,22,304	1,29,805	1,37,268

E: MOFSL Estimates

Financials and valuations

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Basic (INR)									
EPS	8.6	8.7	9.7	10.4	9.7	10.6	11.8	13.2	14.7
Cash EPS	9.2	9.4	11.1	11.3	11.5	12.7	14.1	15.4	17.0
BV/Share	31.9	37.4	43.4	47.4	50.6	55.7	60.3	64.8	69.4
DPS	4.0	4.5	4.8	4.8	5.2	6.7	8.2	9.7	11.2
Payout %	46.6	51.5	48.9	45.8	53.7	63.3	69.3	73.3	76.1
Valuation (x)									
P/E	75.0	73.6	66.3	62.1	66.5	60.8	54.4	48.7	43.8
Cash P/E	70.3	68.3	58.2	56.9	56.2	50.9	45.7	41.9	38.0
EV/Sales	13.0	12.7	11.4	9.9	9.4	8.7	7.8	7.1	6.4
EV/EBITDA	63.6	61.7	53.8	47.8	50.0	44.9	39.2	34.6	31.1
P/BV	20.2	17.2	14.9	13.6	12.7	11.6	10.7	9.9	9.3
Dividend Yield (%)	0.6	0.7	0.7	0.7	0.8	1.0	1.3	1.5	1.7
Return Ratios (%)									
RoE	26.8	25.3	24.1	22.9	19.8	19.9	20.4	21.1	21.9
RoCE	24.4	23.9	22.8	21.2	17.7	17.3	18.3	19.5	20.3
RoIC	53.2	45.9	49.4	60.8	46.1	41.9	51.1	64.8	75.7
Working Capital Ratios									
Debtor (Days)	36	34	21	22	27	26	26	26	26
Asset Turnover (x)	1.4	1.2	1.2	1.2	1.1	1.1	1.1	1.1	1.2
Leverage Ratio									
Debt/Equity (x)	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1

Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
(INR m)									
OP/(loss) before Tax	17,249	17,276	20,787	22,778	22,187	23,587	27,824	31,518	35,278
Int./Div. Received	1,765	2,553	2	39	-1,038	-2,201	-299	-345	-387
Depreciation & Amort.	1,769	2,205	2,401	2,529	3,110	3,992	3,903	4,110	4,316
Interest Paid	-2,002	-2,001	308	386	-2,829	-2,689	950	850	700
Direct Taxes Paid	-3,507	-3,089	-3,611	-5,264	-4,945	-4,939	-6,436	-7,613	-8,708
(Incr)/Decr in WC	-181	-580	7,979	141	-1,601	2,385	-3,854	-200	-233
CF from Oper.	15,092	16,364	27,867	20,609	14,884	20,135	22,089	28,320	30,966
(Incr)/Decr in FA	-2,344	-4,175	-2,311	-3,381	-4,857	-5,609	4,900	-2,300	-2,300
Free Cash Flow	12,748	12,190	25,556	17,228	10,027	14,526	26,988	26,020	28,666
(Pur)/Sale of Invt.	-53,928	-84,788	-13,481	-20,618	-4,950	-7,978	-2,500	-2,500	-2,500
Others	60,600	86,031	-878	1,515	2,736	8,468	-756	-490	-33
CF from Invest.	4,329	-2,931	-16,670	-22,484	-7,072	-5,119	1,643	-5,290	-4,833
Issue of Shares	5	1	-501	-1,006	4	0	0	0	0
(Incr)/Decr in Debt	-2,720	-1,751	129	5,226	488	-472	-200	-200	-200
Dividend Paid	-15,970	-6,178	-5,921	-9,281	-9,213	-9,658	-12,758	-15,416	-18,074
Others	-515	-673	-308	-386	-1,631	-1,483	-950	-850	-700
CF from Fin. Act.	-19,200	-8,601	-6,602	-5,448	-10,352	-11,612	-13,908	-16,466	-18,974
Incr/Decr of Cash	221	4,832	4,596	-7,323	-2,540	3,404	9,824	6,564	7,159
Add: Opening Bal.	3,061	3,282	8,114	12,710	5,387	2,847	6,251	16,075	22,639
Closing Balance	3,282	8,114	12,710	5,387	2,847	6,251	16,075	22,639	29,798

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.